Nanobac Pharmaceuticals Other Current Liabilities

Nanobac Pharmaceuticals posts a other current liabilities of $9.1K as of December 2007. That compares with $520K in the prior-year period — down 98.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Nanobac Pharmaceuticals's other current liabilities was $520K. The latest reading is $9.1K — a 98.3% year-over-year decrease (period ending December 2007). Use the history and growth charts on this page for a longer lookback.

Other Current Liabilities is one piece of Nanobac Pharmaceuticals's financial statement story. At $9.1K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NNBP's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Nanobac Pharmaceuticals's other metric pages and overview cover the third.

Judging Nanobac Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current liabilities easier to interpret. Start with $9.1K here, then scan peer and history charts to see if the gap is persistent.